Furthermore, METTL3 inhibits the efficacy of anti-PD-L1 treatment in breast and bladder cancer, as well as the efficacy of anti-CTLA4 treatment in CRC (24, 26, 29). Here, METTL3 is linked to urinary bladder cancer.